Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.
Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.
复制标题
DOI：
10.1186/s12885-016-2176-6
复制
发表时间：
2016-02-19
期刊：
影响因子：
3.8
通讯作者：
Noguchi K
中科院分区：
文献类型：
--
作者：
Miyoshi Y;Yoneyama S;Kawahara T;Hattori Y;Teranishi J;Kondo K;Moriyama M;Takebayashi S;Yokomizo Y;Yao M;Uemura H;Noguchi K
使用计算机辅助骨扫描诊断系统的骨扫描指数（BSI）有望成为评估骨转移性前列腺癌的客观、定量的临床工具。本研究旨在评估治疗前 BSI 作为未接受激素治疗的前列腺癌骨转移患者的预后因素。该研究纳入了 60 名未接受过激素治疗的骨转移性前列腺癌患者，这些患者最初接受了联合雄激素阻断疗法的治疗。 BONENAVI 系统用于计算 BSI。我们评估了总生存期 (OS) 与治疗前临床病理特征之间的相关性，包括患者年龄、初始前列腺特异性抗原 (PSA) 值、格里森评分、临床 TNM 分期和 BSI。使用Cox比例风险回归模型进行统计分析。中位随访时间为 21.4 个月。 37 名 (61.7%) 患者出现临床或 PSA 进展，其中 18 名 (30.0%) 患者接受多西他赛治疗。 16 名患者 (26.7%) 死亡。在这些死亡中，15 人 (25.0%) 死于前列腺癌。未达到中位 OS。在多变量分析中，年龄和 BSI 是 OS 的独立预后因素。我们通过量化 C 指数来评估模型的辨别能力，包括或排除 BSI。 BSI 将操作系统的 C 指数从 0.751 提高到 0.801。 BSI ≤ 1.9 的患者未达到中位 OS，BSI > 1.9 的患者中位 OS 为 34.8 个月 (p = 0.039)。治疗前 BSI 和患者年龄是未经激素治疗的骨转移性前列腺癌患者的独立预后因素。
The bone scan index (BSI) using a computer-aided diagnosis system for bone scans is expected to be an objective and quantitative clinical tool for evaluating bone metastatic prostate cancer. This study aimed to evaluate the pretreatment BSI as a prognostic factor in hormone-naive prostate cancer patients with bone metastases. The study included 60 patients with hormone-naive, bone metastatic prostate cancer that was initially treated with combined androgen blockade therapy. The BONENAVI system was used for calculating the BSI. We evaluated the correlation between overall survival (OS) and pretreatment clinicopathological characteristics, including patients’ age, initial prostate-specific antigen (PSA) value, Gleason scores, clinical TNM stage, and the BSI. Cox proportional hazards regression models were used for statistical analysis. The median follow-up duration was 21.4 months. Clinical or PSA progression occurred in 37 (61.7 %) patients and 18 (30.0 %) received docetaxel. Death occurred in 16 (26.7 %) patients. Of these deaths, 15 (25.0 %) were due to prostate cancer. The median OS was not reached. In multivariate analysis, age and the BSI were independent prognostic factors for OS. We evaluated the discriminatory ability of our models, including or excluding BSI by quantifying the C-index. The BSI improved the C-index from 0.751 to 0.801 for OS. Median OS was not reached in patients with a BSI ≤1.9 and median OS was 34.8 months in patients with a BSI >1.9 (p = 0.039). The pretreatment BSI and patients’ age are independent prognostic factors for patients with hormone-naive, bone metastatic prostate cancer.